Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines

Abstract

IntroductionA second generation HPV vaccine has been developed for the prevention of anogenital cancers and precancerous lesions of the cervix, vulva, vagina, anus and of genital warts due to nine HPV types.We estimated the annual burden of these diseases attributable to the nine HPV types compared to HPV types from first generation vaccines in women and men in Europe.Material and methodsIncidence rates from the IARC database, cancer registries, the literature and Eurostat population data were used.The burden attributable to the HPV types targeted by both vaccines was estimated by applying the relative contribution of the respective HPV types from epidemiological studies.ResultsIn 2013, the number of new anogenital HPV-attributable cancers was 44,480 with 39,494 of these cases related to second vs. 33,285 to first generation vaccine types.Among the 284,373 to 541,621 new HPV-attributable anogenital precancerous lesions 235,364–448,423 and 135,025–256,830 were estimated to be related to second and first generation vaccine types, respectively.The annual number of new genital warts was 753,608–935,318, with 90% related to HPV6/11.ConclusionsThese data demonstrate how the large public health impact that was achieved by the first generation HPV vaccines could be further increased by second generation vaccines.

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

“…Data confirm that types 16, 18, 31, 33, 45, 52 and 58 are amongst those most frequently detected [13]. Therefore, the nine-valent vaccine is expected to provide coverage against the majority of high-risk HPV types with carcinogenic properties [11].…”

Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

“…Moreover, HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 are associated with 78% and 91% of CIN2 and CIN3 occurrences, respectively . In Europe, HPV 16 and 18 account for approximately 72.8% of all cervical cancers and 45.5% of high‐grade cervical dysplasia, whereas HPV genotypes targeted by the nonavalent vaccine account for 89% of cervical cancers and 82.3% of high‐grade cervical lesions . In Portugal, HPV 16 and 18 have been identified as accounting for 54.4% of CIN2, 62.9% of CIN3, and 77.4% of ICC based on CLEOPATRE II study data, and the present analysis demonstrated that HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for 89.3%, 97.1%, and 96.8%, respectively.…”

Tendencias en la investigación del virus de papiloma humano en Latinoamérica frente a los países de altos ingresos

“…En Europa, 21 países han introducido la vacuna contra VPH; de estos, solo 7 países (Dinamarca, Italia, Luxemburgo, Portugal, Suiza, España y Reino Unido) han alcanzado una tasa de cobertura ≥ 80 % (16,103). Si esta es la contraproducente situación sanitaria relacionada con la vacunación en los países con altos ingresos, con estructuras socio-sanitarios sólidas, donde en la mayoría aún no se está logrando una cobertura del 100 % de mujeres vacunadas, qué se puede esperar de los países con limitaciones sanitarias como los PMBI (99,(103)(104)(105).…”